Click to copy

Press release content from Business Wire. The AP news staff was not involved in its creation.

Click to copy

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2019 - ResearchAndMarkets.com

November 22, 2019

DUBLIN--(BUSINESS WIRE)--Nov 22, 2019--

The “Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 7, 8, 1, 12, 3 and 1 respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

Reasons to Buy